A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Multi-Center Study to Assess the Safety and Efficacy of Exenatide Once Weekly in Adolescents With Type 2 Diabetes
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Amylin Pharmaceuticals; AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 22 Feb 2017 Planned End Date changed from 1 Jun 2023 to 1 Feb 2023.
- 15 Sep 2016 Planned number of patients changed from 80 to 77.